Nabriva Therapeutics plc (NBRV) Misses Q3 EPS by 18c

Nabriva Therapeutics plc (NASDAQ: NBRV) reported Q3 EPS of ($4.21), $0.18 worse than the analyst estimate of ($4.03). Revenue for the quarter came in at $9.15 million versus the consensus estimate of $11.05 million.

For earnings history and earnings-related data on Nabriva Therapeutics plc (NBRV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c